Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 27;36(1):24.
doi: 10.1007/s12022-025-09866-z.

Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up

Affiliations

Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up

Ashley L Kiemen et al. Endocr Pathol. .

Abstract

The clinical behavior of well-differentiated pancreatic neuroendocrine tumors (PanNETs) is difficult to predict. In order to define, more accurately, prognosticators for patients with a surgically resected PanNET, the pathologic features and Ki-67 immunolabeling indexes of PanNETs resected from 904 consecutive patients at an academic tertiary care hospital were correlated with patient outcome. The mean patient age at surgery was 56.6 years (SD 14.0), 477 were male (52.8%), and 7882 person-years of follow-up were obtained (mean 8.8 years, SD 6.5). The 10-year survival was 81% (95% CI: 77,86%) for patients with G1 PanNETs (Ki-67 <3%), 68% (95% CI: 61,76%) for patients with G2a PanNETs (Ki-67 3 - <10%), 44% (95% CI: 29,66%) for patients with G2b PanNETs (Ki-67 of 10%- ≤20%), and 23% (95% CI: 8,61%) for patients with G3 PanNETs. Vascular invasion (HR 3.0, p <0.0001), tumor size ≥ 2 cm (HR 2.88, p <0.0001), perineural invasion (HR 2.42, p<0.0001), and positive margins (HR 2.18, p <0.0001) were associated with worse overall survival. Insulinoma (HR 0.34, p=3e-04), sclerosing variant (HR 0.47, p=0.05), and cystic variant (HR 0.61, p=0.05) were associated with improved overall survival. T, N and M stages were all statistically significant classifiers of overall survival. Similar associations were found with respect to disease relapse. There was a significant (P<0.001) increase in the proportion of patients diagnosed with stage I vs stage IV disease over time. This study supports the classification of PanNETs into four grades (G1, G2a, G2b, and G3) based on Ki-67 labeling, which allows a more accurate prognostic assessments of patients.

Keywords: Grade; Ki-67; PanNET; Prognosis; Stage; Vascular invasion; Well-differentiated pancreatic neuroendocrine tumor.

PubMed Disclaimer

Conflict of interest statement

Declarations. The authors declare that they do not have any financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A Kaplan-Meier curves for survival for the entire cohort. B Changes in the hazard ratio for death with increases in tumor size, estimated with restricted cubic splines. The plotted results represent the hazard ratio for different values of the continuous predictor (tumor size), visualizing any non-linear effects captured by the restricted cubic spline. C Kaplan-Meier curves for overall survival, separately according to grade. D Changes in the hazard ratio for death with increases in Ki-67, estimated with restricted cubic splines. The plotted results represent the hazard ratio for different values of the continuous predictor (Ki-67), visualizing any non-linear effects captured by the restricted cubic spline. E Predicted probability [95% CI] of being diagnosed with stage I, II, III, or IV disease (y-axis) by year of surgery grouped into quintiles (x-axis). Probabilities and corresponding odds ratios for the average relative change in the odds of a stage I, II, or III diagnosis compared to stage IV with every increasing quintile of year of surgery, adjusted for age and sex, are estimated from a multinomial regression model

Update of

Similar articles

References

    1. Dasari, A. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3, 1335-1342 (2017). 10.1001/jamaoncol.2017.0589 - PMC - PubMed
    1. Pathak, S., Starr, J. S., Halfdanarson, T. & Sonbol, M. B. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab 18, 377-385 (2023). 10.1080/17446651.2023.2237593 - PubMed
    1. Thiis-Evensen, E. & Boyar Cetinkaya, R. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021. J Neuroendocrinol 35, e13264 (2023). 10.1111/jne.13264 - PubMed
    1. Xu, Z. et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 4, e2124750 (2021). 10.1001/jamanetworkopen.2021.24750 - PMC - PubMed
    1. Sonbol, M. B. et al. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist 27, 573-578 (2022). 10.1093/oncolo/oyac049 - PMC - PubMed

LinkOut - more resources